Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Qualigen Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Qualigen Therapeutics, Inc.

QLGN

Qualigen Therapeutics, Inc.

About Qualigen Therapeutics, Inc.

Qualigen Therapeutics is an early-stage biotech company developing cancer treatments, focusing on small molecule therapeutics targeting genetic structures like G-quadruplexes and RAS oncogenes. Its pipeline includes QN-302 for pancreatic cancer and Pan-RAS inhibitors for multiple cancers. The company collaborates with academic institutions, advances clinical trials, and seeks regulatory approval, aiming to address unmet medical needs in oncology markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Qualigen Therapeutics, Inc.

1
1
Qualigen Therapeutics, Inc. AIxCrypto Holdings Reports $6.08 Million Net Loss in Q1 2026

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
Qualigen Therapeutics, Inc. AIxCrypto Holdings Reports $16.97 Million Net Loss and Strategic Shift in Latest 10-K Filing

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Qualigen Therapeutics, Inc. Qualigen Therapeutics Reports $6.4 Million Net Loss and Improved Cash Position in Latest Filing

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Qualigen Therapeutics, Inc. Qualigen Therapeutics Reports $1.7 Million Net Loss and Increased Financial Challenges in Latest Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Qualigen Therapeutics, Inc. Qualigen Therapeutics Reports $2.65 Million Net Loss in Q1 2025 Amid Rising Expenses

Via official filing (AI summary) | 11 months ago | 0 comments

6
1
Qualigen Therapeutics, Inc. Qualigen Therapeutics Reports $6.3 Million Net Loss for Fiscal Year 2024, Seeks Additional Financing

Via official filing (AI summary) | 11 months ago | 0 comments

7
1
Qualigen Therapeutics, Inc. Qualigen Therapeutics Reports Improved Financials, Reduced Losses in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments